The mechanism by which mutations in NOD2 predispose to Crohn's disease (CD) is incompletely understood. In mice, NOD2 has been found to function as a negative regulator of Toll-like receptor 2 (TLR2) signaling. In contrast, studies in humans so far showed no negative regulatory interaction between NOD2 and TLR2, and in fact suggest a synergistic effect between the two. Here, we show that this interaction is dose dependent. Adding low doses of muramyl dipeptide (MDP) to TLR2 primed monocytes results in a significant increase in cytokine production, whereas adding higher doses of MDP led to a striking downregulation of the responses. This downregulation by high-dose MDP does not occur in monocytes from NOD2-deficient patients. The inhibitory role of NOD2 at high concentrations of MDP implicates a safety mechanism to prevent exaggerated antibacterial immune responses in the gut to high or perpetuating bacterial load. This regulatory mechanism is lost in NOD2-deficient CD patients.
Mutations in the gene encoding nucleotide-binding oligomerization domain 2 (NOD2) are strongly associated with an increased risk of developing Crohn's disease (CD), 1,2 a chronic inflammatory disorder of the gastrointestinal tract. NOD2 is a member of the NODleucine-rich repeat (LRR) protein family, which comprises of proteins that all consist of a C-terminal ligand recognition domain, a central NOD domain, and an N-terminal protein-protein interaction domain. 3 Homozygosity for mutations in the LRR of NOD2 results in a 20-40 times higher risk of developing CD, whereas the risk of developing the disease is approximately four times higher in individuals that are heterozygotic. 4 How the alterations in the NOD2 protein exert their effects on disease susceptibility is not completely clear, not in the last place because this sensor of the bacterial peptidoglycan component muramyl dipeptide (MDP) is expressed in various cell types, including Paneth cells as well as macrophages and dendritic cells. Furthermore, activation of NOD2 results in activation of multiple pathways, including the nuclear factor (NF)-kB and mitogen-activated protein kinase pathways, leading to a variety of responses. 5, 6 Both NOD2 and Toll-like receptor 2 (TLR2) are activated by the same bacterial products (that is, peptidoglycan derivates). 6 In mice, NOD2 has been suggested to play a role as a negative regulator of TLR2 signaling, leading to excessive NF-kB dependent IL-12 production associated with the strong T h 1 response seen in murine colitis in NOD2 deficient mice. 7, 8 In contrast, in human no indications for a negative regulatory interaction between NOD2 and TLR2 exist. Data in human on the simultaneous activation through NOD2 and TLRs, including TLR2, show a positive synergistic effect, an effect that is lost in individuals bearing NOD2 mutations. [9] [10] [11] [12] This is accompanied by a loss of NF-kB signaling function leading to impaired cytokine production after NOD2 stimulation, and to an impaired costimulatory effect of NOD2 signaling on TLR-mediated cytokine production. [9] [10] [11] [12] This effect appears contradictory to the elevated levels of NF-kB activation-dependent T h 1 cytokines typically found in the inflamed tissues from patients with CD. 13, 14 In the current study, we intended to bridge these seemingly contradictory findings. We hypothesized that the mode of interaction between NOD2 and TLR2 may be dose dependent and that part of the controversy may be related to differences in experimental design and stimulation dose. To test this hypothesis, we isolated monocytes from 5 healthy donors and 15 CD patients divided in three groups of 5 carrying 0, 1 or 2 mutant NOD2 alleles, respectively. All patients had inactive disease at the time of the study and were on minimum or no drug treatment. After isolation and an overnight rest, cells were stimulated with low doses of either the synthetic TLR2 ligand Pam 3 CSK 4 (Pam), or the TLR4 ligand lipopolysaccharide (LPS). In addition, different concentrations of MDP (0, 1, 10, 25 and 100 mg ml
À1
) were added and production of TNF-a, IL-6 and IL-12 was determined in the cell culture supernatant.
Stimulation of cells with either LPS or Pam alone resulted in significant upregulation of cytokine production as compared to unstimulated cells. Stimulation of cells with MDP alone resulted only in a small and Figure 1 TNF-a production in relation to NOD2 genotype in monocytes stimulated with different TLR ligands and different doses of MDP. Monocytes were isolated from 50 ml of heparinized peripheral blood by density gradient centrifugation. Cells were cultured in triplicate (10 5 cells per 100 ml culture medium) and allowed to rest overnight. They were then stimulated for 3 h with pure synthetic TLR2 ligand (Pam3CSK4; 50pgml
) and different concentrations of MDP (0, 1, 10, 25 and 100 mg ml
). TNF-a was determined by enzyme-linked immunosorbent assay (ELISA). (A) TNF-a secretion after stimulation with the TLR2 ligand Pam3CSK4. Each graph includes five different donors stimulated with three different MDP doses (0 mg ml À1 (open bars); 100 mg ml À1 (black bars), whereas the gray bars represents the low MDP dose in the 1-25 mg ml À1 range that resulted in optimal cytokine secretion for that individual). CD, Crohn's disease. Table 1a represent the absolute values of TNF-a secretion. (B) TNF-a secretion after stimulation of cells with the TLR4 ligand LPS (10 ng ml
) and the different doses of MDP (also see Table 1b ). The individual genotypes of the heterozygous and NOD2-deficient patients are provided in Supplementary Table 1. nonsignificant increase of cytokine expression in individuals with at least one functional NOD2 allele. The magnitude of this response was 5-10 folds lower as compared to stimulation with the TLR ligands and independent of the dose (results not shown). As expected, MDP stimulation of cells in NOD2-deficient individuals did not result in any upregulation of cytokine expression.
Shown in Figure 1A and Table 1a is the TNF-a response of monocytes from different groups of CD patients and healthy controls after combined stimulation with 50 ng ml À1 of the TLR2 ligand Pam and increasing doses of MDP. Adding MDP in the dose range of 1-25 mg ml À1 to Pam-stimulated monocytes resulted in a dose-dependent upregulation of TNF-a responses in 13 out of 15 individuals (either patients or healthy controls) carrying at least one wild-type NOD2 allele. The dose of MDP needed for maximum cytokine production differed somewhat from person to person and was in the range between 1 and 25 mg ml
. For clarity of the graphs, we show only the dose that resulted in the highest cytokine production for that particular individual (referred to as low dose MDP, hereafter). Overall, the mean TNF-a response among these individuals increased from 865 (range 28-2761) pg ml À1 after Pam stimulation alone to 1556 (range 176-4073) pg ml À1 after Pam þ low dose MDP, Po0.0001). Strikingly, adding a higher dose of 100 mg ml À1 MDP resulted in a marked reduction of TNF-a responses as compared to the low dose and at this concentration of MDP, TNF-a values returned to, or below the baseline level that was seen after Pam stimulation alone (754 pg ml À1 (range 85-1857), P ¼ 0.0002 as compared with the low MDP dose). The magnitude of this response was particularly evident in individuals without any mutation in NOD2 and less pronounced in heterozygous individuals, which is indicative of a gene-dosage effect (Table 1a) .
As expected, adding MDP (either low or high dose) did not result in upregulation of TNF-a in monocytes from patients carrying mutations on both alleles (referred to here as NOD2-deficient patients; Figure 1A and Table 1a ). Thus, in sharp contrast to the biphasic response seen in individuals carrying at least one NOD2 wild-type allele, no effect of MDP on the TLR2-induced response was seen in NOD2-deficient individuals.
One could argue that the MDP concentration added is fairly high, and that the effects seen in cytokine production are not due to an active inhibition of the TLR2 signaling, but due to toxic effects from the high MDP concentrations. The cells that received the high MDP dose however, remained viable even after prolonged culture. In addition, as shown in Figure 1B and Table 1b , the decrease in cytokine production seen after adding the high dose of MDP in Pam-stimulated monocytes was not observed in cells costimulated with the TLR4 ligand LPS instead of Pam. Taken together, these findings indicate that NOD2 signaling influences TLR2 signaling in a biphasic fashion, first augmenting the response, and at a higher dose, diminishing the response. This response is TLR2 specific, independent from disease status and abrogated in NOD2-deficient individuals.
With regard to IL-6, a similar response as seen for TNF-a was found. Thus, an initial increase in IL-6 production was seen after addition of the low dose of MDP to monocytes primed with Pam (from 698 pg ml À1 (range 100-2217) to 1592 pg ml À1 (range 518-5640), P ¼ 0.001). Adding the high MDP dose resulted in a significant lower IL-6 production (783 pg ml À1 (range 109-2923); P ¼ 0.004 as compared to the low MDP dose). Similar to the results found for TNF-a, no effect of MDP on IL-6 production was seen in monocytes from NOD2-deficient patients. Also, this biphasic response to MDP was not seen in monocytes primed with LPS instead of Pam (see Supplementary Information file for the corresponding graphs and tables).
For IL-12, a similar pattern was also found. Thus, IL12p40 increased from 8075 (range 1611-18611) pg ml
after Pam alone to 13148 (range 2432-30648) pg ml À1 after addition of the low dose MDP (Po0.0001) and returned to 8667 (range 546-22283) pg ml À1 after adding the high MDP dose (Po0.0001) in individuals carrying at least one wild-type allele. For IL-12p70 the same pattern was found, although it must be noted that similar to the findings in mice, the IL-12p70 responses were generally low. Again, no measurable effect of MDP on IL-12p40 and IL-12p70 production was found in monocytes from NOD2-deficient patients. Similarly, this biphasic response was not seen after costimulation with LPS instead of Pam (see Supplementary Information file) .
To further substantiate these findings, we assessed NF-kB activation in a small group of individuals. Monocytes from a donor without NOD2 mutations, a NOD2 heterozygous donor and a NOD2-deficient donor were stimulated with either Pam, Pam and low-dose MDP, and Pam with the high dose of MDP. As can be seen from Figure 2 , the amount of translocated NF-kB p50 and p65 subunits in the NOD2 competent donor, and to a lesser extent in the heterozygous donor followed a similar pattern as the cytokine responses, although it must be noted that this experiment was too small to draw definitive conclusions on the effect of MDP on NF-kB translocation. This response was again not seen in the NOD2-deficient individual. Interestingly, this response was not reflected in c-Rel translocation. In fact, c-Rel was hardly upregulated, suggesting that the p50 and p65 units may be stronger induced by NOD2 activation.
The data presented here show that TLR2 signaling and NOD2 signaling in human monocytes are linked. In monocytes that are activated with TLR ligands and low levels of the MDP, a synergistic effect is seen, correlating with earlier reports. However, when high doses of MDP are used this synergistic effect is lost in the case of TLR2 signaling, but not in the case of TLR4. CD patients with both NOD2 alleles mutated do not show this downregulation, whereas a gene dosage effect is seen in patients with one allele affected. The importance of the linkage between TLR2 and NOD2 signaling pathways, which we show here for the fist time in human, may be related to the fact that both TLR2 and NOD2 recognize closely related structures with MDP being a derivative of the TLR2 ligand peptidoglycan. The biphasic response seen with lower ligand stimulation being synergistic, and only at high ligand levels leading to negative regulation, points to complex signaling pathways. The loss of regulatory function of the NOD2 molecule, as inferred from our experiments, can explain the excessive T h 1 responses seen in IBD patients and the strong linkage of the mutation of NOD2 and disease. It remains to be seen whether this function is important at the initial stage of recognition of microbial pathogens or plays a role at later stages of inflammation. The biphasic effects of NOD2 stimulation on TLR2 signaling could also be reflected in the overall effects of NOD2 mutation on the pathogenesis of CD.
First, an increase in susceptibility to infection by commensal bacteria could be caused by a reduced barrier function of the intestinal epithelium, due to impaired a-defensin production by Paneth cells, 15 or a reduced IL-1b responses to bacterial challenge 16 combined with a less strong initial potentiating of TLR responses. [9] [10] [11] [12] This way NOD2 variants could lead to a weaker mucosal defense, leading to overgrowth of commensal bacteria.
Second, when there is an ongoing mucosal immune response, and the negative regulation of NOD2 on specifically TLR2 is lacking, this can result in an unwanted strong response. 7, 8 Without a proper downmodulation of the immune response, this provides an activated immune setting for ongoing inflammation as seen in CD. That the expression of NOD2 can be induced in T cells under the influence of pro-inflammatory factors such as TNF-a, 17 adds another level of complexity to the etiology of CD and suggests that NOD2 could also play a role in later stages of the disease when the adaptive immune system gets involved.
Clearly, NOD2 is a key player in innate immune responses of many cell types. The lack of an initial strong response, combined with subsequent insufficient TLR2 inhibition due to NOD2 defects could be an attractive mechanism that plays an important part in CD pathogenesis. To determine the exact role(s) of NOD2 in the etiology of CD, it will be important to dissect the particular role of NOD2 and its interaction with TLR2 in the various cell types involved in the intestinal homeostasis, such as epithelial Paneth cells and hemopoietic immune cells.
